ExodusPoint Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

ExodusPoint Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$293K	Buy	10,851 +4,269	+65%	+$143K	﹤0.01%	1315
2025 Q4	$282K	Sell	6,582 -9,785	-60%	-$369K	﹤0.01%	1323
2025 Q3	$464K	Buy	+16,367	New	+$490K	﹤0.01%	1201
2025 Q1	–	Sell	-15,483	Closed	-$260K	–	1920
2024 Q4	$260K	Buy	+15,483	New	+$297K	﹤0.01%	1316
2023 Q1	–	Sell	-4,016	Closed	-$60K	–	2070
2022 Q4	$60K	Sell	4,016 -31,308	-89%	-$287K	﹤0.01%	1540
2022 Q3	$417K	Buy	+35,324	New	+$478K	0.01%	1430
2022 Q2	–	Sell	-41,877	Closed	-$1.25M	–	2365
2022 Q1	$1.25M	Buy	41,877 +5,650	+16%	+$153K	0.02%	1021
2021 Q4	$960K	Buy	36,227 +33,717	+1,343%	+$1.02M	0.01%	1093
2021 Q3	$91K	Buy	+2,510	New	+$98.8K	﹤0.01%	1916
2021 Q2	–	Sell	-2,647	Closed	-$91K	–	2729
2021 Q1	$91K	Sell	2,647 -321	-11%	-$12.7K	﹤0.01%	1990
2020 Q4	$104K	Sell	2,968 -1,023	-26%	-$29.6K	﹤0.01%	1828
2020 Q3	$96K	Buy	3,991 +1,681	+73%	+$41.3K	﹤0.01%	1595
2020 Q2	$42K	Buy	+2,310	New	+$41.6K	﹤0.01%	1690
2020 Q1	–	Sell	-1,112	Closed	-$24K	–	1555
2019 Q4	$24K	Buy	+1,112	New	+$22.9K	﹤0.01%	1466
2019 Q3	–	Sell	-1,898	Closed	-$50K	–	1591
2019 Q2	$50K	Buy	+1,898	New	+$42.8K	﹤0.01%	1052

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ExodusPoint Capital Management's RIGL Position: Q1 2026 in Review

ExodusPoint Capital Management increased its Rigel Pharmaceuticals (RIGL) stake by 65% in Q1 2026, buying an estimated $143K and bringing the position to 10,851 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #1315.

ExodusPoint Capital Management first reported a position in RIGL in Q2 2019 and has held it in 15 quarters since. The position peaked at $1.25M in Q1 2022. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

ExodusPoint Capital Management held 10,851 shares of Rigel Pharmaceuticals worth $293K as of Q1 2026.
ExodusPoint Capital Management bought 4,269 Rigel Pharmaceuticals shares in Q1 2026, an estimated $143K.
Rigel Pharmaceuticals made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1315 holding.
ExodusPoint Capital Management first reported a position in Rigel Pharmaceuticals in Q2 2019 and has held it in 15 quarters since.
ExodusPoint Capital Management's Rigel Pharmaceuticals position peaked at $1.25M in Q1 2022.
159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.